Drospirenone Synthesis via Segmented Esterification and Methylene Introduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing industrial processes for synthesizing drospirenone face challenges such as low yields, the use of hazardous materials, and scalability issues, which complicate the production of pure intermediates and end-products necessary for pharmaceutical applications.
Innovation Solution
A novel 8-step industrial process involving the esterification of 15α-hydroxy-androst-4-ene-3,17-dione with a C1-6 alkane carboxylic acid derivative, followed by reactions with trialkyl orthoformiate and trimethylsulfoxonium methylide, to introduce methylene groups and form the desired γ-lactone structure, allowing for the separation and purification of drospirenone through chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional multi-step synthesis routes are used, then drospirenone can be produced, but the yields are low and purification is complex
Solution Approach 1:
The synthesis route is divided into distinct modular steps: esterification, orthoformiate reaction, and sulfoxonium methylide treatment. Each step produces a discrete intermediate that can be independently optimized and purified, reducing overall process complexity while maintaining high yields.
Solution Approach 2:
The patent introduces specific intermediate compounds (esterified products, orthoformiate adducts, and sulfoxonium derivatives) that facilitate the transformation. These intermediates serve as stable, isolable species that simplify purification steps compared to direct multi-step conversions.
2Ease of manufacture
If conventional synthesis methods are applied, then drospirenone intermediates can be obtained, but hazardous materials must be used
Solution Approach 1:
The patent employs readily available, non-hazardous reagents such as C1-6 alkane carboxylic acid derivatives, trialkyl orthoformiates, and trimethylsulfoxonium methylide. These reagents are safer alternatives to traditional hazardous chemicals while maintaining synthetic efficiency.
Solution Approach 2:
The synthesis conditions are optimized to use mild, safe parameters: standard temperature ranges, non-toxic solvents, and controlled pH conditions. This eliminates the need for hazardous materials while preserving product yield and purity.
3Manufacturing precision
If laboratory-scale synthesis procedures are used, then drospirenone can be prepared, but scale-up to industrial production is problematic
Solution Approach 1:
The synthesis protocol is designed with universal applicability across different scales. The reaction conditions, reagent ratios, and purification methods are standardized to function equally well in laboratory and industrial settings, enabling straightforward scale-up without compromising product quality.
Solution Approach 2:
The process parameters are optimized for both small-scale precision and large-scale efficiency. Reaction temperatures, times, and concentrations are set to maintain high purity while allowing increased throughput. The use of robust, non-hazardous reagents further enhances scalability by improving safety and handling at industrial volumes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves higher yields and purity of intermediates and the final product, avoiding the use of hazardous materials and simplifying the scale-up of drospirenone production while meeting pharmacopeial requirements.
Implementation Method 1
esterification of 15α-hydroxy-androst-4-ene-3,17-dione with a C1-6 alkane carboxylic acid derivative
Implementation Method 2
reactions with trialkyl orthoformiate and trimethylsulfoxonium methylide, to introduce methylene groups
Implementation Method 3
allowing for the separation and purification of drospirenone through chromatography
Data Source
AI summary
The invention relates to an industrial process for the preparation of 17-hydroxy-6β,7β;15β,16β-bismethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone of formula (I), and to the key-intermediates for this process.